Sunday May 5, 2024 | Last Update: May 5, 2024 EDT
Biogen Inc's multiple sclerosis drugs have failed to reach analysts sales expectations in the second-quarter, prompting the company to slash its forecast for 2015, according to a report from Reuters.
Read more >>
Just In
Most Read
1
2
3
4
5